文献速递慢性肾脏病血液净化与透析

司美格鲁肽在不同基线HbA1c、血压、体重和蛋白尿水平下对肾功能的影响:SUSTAIN 6与PIONEER 6分析

Effect of semaglutide on kidney function across different levels of baseline HbA1c, blood pressure, body weight and albuminuria in SUSTAIN 6 and PIONEER 6.
PubMed 文献 · Nephrol Dial Transplant · 2025-01-01

本事后分析汇总SUSTAIN 6与PIONEER 6数据,评估2型糖尿病伴高心血管风险人群中,司美格鲁肽对eGFR斜率的影响是否受基线HbA1c、收缩压、BMI及白蛋白尿状态影响。结果显示,司美格鲁肽组eGFR斜率绝对获益在各亚组中一致,交互作用P值均大于0.5。

要点

  • 司美格鲁肽较安慰剂显著改善eGFR斜率,汇总分析差异为0.59 mL/min/1.73 m2/年。
  • SUSTAIN 6中eGFR斜率差异为0.60 mL/min/1.73 m2/年。
  • 获益在HbA1c、血压、BMI及UACR各亚组中一致,交互作用P值均大于0.5。

核心结论

  • 司美格鲁肽较安慰剂降低慢性肾脏病进展风险,且不受基线HbA1c、血压、BMI和UACR水平影响。

研究设计与样本

  • 事后分析汇总SUSTAIN 6与PIONEER 6数据,按基线HbA1c、收缩压、BMI及SUSTAIN 6中UACR分层分析eGFR斜率变化。

主要发现

  • 汇总分析中eGFR斜率估计绝对治疗差异为0.59(95%CI 0.29;0.89)mL/min/1.73 m2/年,支持司美格鲁肽。
  • SUSTAIN 6中eGFR斜率估计绝对治疗差异为0.60(95%CI 0.24;0.96)mL/min/1.73 m2/年。
  • 所有HbA1c、血压、BMI和UACR亚组的绝对获益一致,交互作用P值均大于0.5。

关键数值与推荐

  • 基线HbA1c分层:<8%/≥8%(<64/≥64 mmol/mol)。
  • 基线收缩压分层:<140/90/≥140/90 mmHg。
  • 基线BMI分层:<30/≥30 kg/m2。
  • SUSTAIN 6中基线UACR分层:<30/30-300/>300 mg/g。

临床怎么用

  • 对于2型糖尿病伴高心血管风险患者,无论基线HbA1c、血压、BMI或白蛋白尿水平如何,司美格鲁肽均可考虑用于延缓eGFR下降。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: This post hoc analysis explored the effects of semaglutide on estimated glomerular filtration (eGFR) slope by baseline glycemic control, blood pressure (BP), body mass index (BMI) and albuminuria status in people with type 2 diabetes and high cardiovascular risk. METHODS: Pooled SUSTAIN 6 (Trial to Evaluate Cardiovascular and Other Long-Term Outcomes With Semaglutide in Subjects With Type 2 Diabetes) and PIONEER 6 (A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes) data were analyzed for change in eGFR slope by baseline hemoglobin A1c (HbA1c) (<8%/≥8%; <64/≥64 mmol/mol), systolic BP (<140/90/≥140/90 mmHg) and BMI (<30/≥30 kg/m2). SUSTAIN 6 data were analyzed by baseline urinary albumin:creatinine ratio (UACR; <30/30-300/>300 mg/g). RESULTS: The estimated absolute treatment differences overall in eGFR slope (95% confidence intervals) favored semaglutide versus placebo in the pooled analysis [0.59 (0.29; 0.89) mL/min/1.73 m2/year] and in SUSTAIN 6 [0.60 (0.24; 0.96) mL/min/1.73 m2/year]; the absolute benefit was consistent across all HbA1c, BP, BMI and UACR subgroups (all P-interaction >.5). CONCLUSION: A clinically meaningful reduction in risk of chronic kidney disease progression was observed with semaglutide versus placebo regardless of HbA1c, BP, BMI, and UACR levels.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Apperloo EM, Cherney DZI, Kuhlman AB, et al. Effect of semaglutide on kidney function across different levels of baseline HbA1c, blood pressure, body weight and albuminuria in SUSTAIN 6 and PIONEER 6. Nephrol Dial Transplant. 2025. PMID: 38955363. doi:10.1093/ndt/gfae150

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。